Compare Stocks

Date Range: 

 GW PharmaceuticalsAscendis Pharma A/SUltragenyx PharmaceuticalArrowhead PharmaceuticalsTG Therapeutics
SymbolNASDAQ:GWPHNASDAQ:ASNDNASDAQ:RARENASDAQ:ARWRNASDAQ:TGTX
Price Information
Current Price$218.96$132.90$114.53$66.38$40.20
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.31.51.71.51.8
Analysis Score1.13.54.43.43.4
Community Score3.02.63.32.53.3
Dividend Score0.00.00.00.00.0
Ownership Score1.70.80.01.71.7
Earnings & Valuation Score0.60.60.60.00.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$204.09$192.22$143.94$85.31$63.33
% Upside from Price Target-6.79% downside44.64% upside25.68% upside28.51% upside57.55% upside
Trade Information
Market Cap$6.86 billion$7.14 billion$7.73 billion$6.91 billion$5.69 billion
Beta2.150.772.191.622.28
Average Volume899,737212,819448,226787,1671,502,836
Sales & Book Value
Annual Revenue$311.33 million$14.98 million$103.71 million$87.99 million$150,000.00
Price / Sales22.05476.8674.5078.5237,913.42
Cashflow$0.01 per shareN/AN/AN/AN/A
Price / Cash18,588.22N/AN/AN/AN/A
Book Value$23.48 per share$15.87 per share$11.32 per share$4.51 per share$0.39 per share
Price / Book9.338.3710.1214.72103.08
Profitability
Net Income$-9,020,000.00$-244,180,000.00$-402,730,000.00$-84,550,000.00$-172,870,000.00
EPS($0.24)($5.25)($7.36)($0.84)($1.83)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E Ratio608.22N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-11.05%-4,042.79%-119.19%-96.09%-151,798.69%
Return on Equity (ROE)-7.46%-55.72%-50.69%-17.37%-223.96%
Return on Assets (ROA)-6.13%-49.42%-26.87%-15.19%-108.08%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.01%N/AN/AN/A0.09%
Current Ratio5.13%14.80%4.33%7.92%3.35%
Quick Ratio4.31%14.80%4.26%7.92%3.35%
Ownership Information
Institutional Ownership Percentage81.00%N/AN/A65.52%65.73%
Insider Ownership Percentage3.10%40.00%8.20%4.00%13.20%
Miscellaneous
Employees1,161482893232272
Shares Outstanding31.35 million53.75 million67.46 million104.09 million141.47 million
Next Earnings Date8/5/2021 (Estimated)5/18/2021 (Estimated)7/29/2021 (Estimated)8/4/2021 (Estimated)5/10/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
TG Therapeutics (TGTX) Set to Announce Earnings on MondayTG Therapeutics (TGTX) Set to Announce Earnings on Monday
americanbankingnews.com - May 7 at 10:12 AM
TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business UpdateTG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business Update
finance.yahoo.com - May 6 at 11:57 AM
TG Therapeutics, Inc. (NASDAQ:TGTX): When Will It Breakeven?TG Therapeutics, Inc. (NASDAQ:TGTX): When Will It Breakeven?
finance.yahoo.com - May 4 at 5:51 PM
TG Therapeutics Inc. (TGTX) investors to reap big returns againTG Therapeutics Inc. (TGTX) investors to reap big returns again
marketingsentinel.com - May 4 at 7:49 AM
Earnings Preview: TG Therapeutics (TGTX) Q1 Earnings Expected to DeclineEarnings Preview: TG Therapeutics (TGTX) Q1 Earnings Expected to Decline
finance.yahoo.com - May 3 at 4:48 PM
What Will TG Therapeutics, Inc. (NASDAQ:TGTX) Be Like After It Drops -27.65% From Its Highs?What Will TG Therapeutics, Inc. (NASDAQ:TGTX) Be Like After It Drops -27.65% From Its Highs?
marketingsentinel.com - April 30 at 6:21 PM
TGTX Jan 2022 17.000 putTGTX Jan 2022 17.000 put
in.finance.yahoo.com - April 30 at 1:21 PM
TGTX Jan 2023 32.000 callTGTX Jan 2023 32.000 call
in.finance.yahoo.com - April 30 at 1:21 PM
TG Therapeutics (NASDAQ:TGTX) Shares Up 4.5%TG Therapeutics (NASDAQ:TGTX) Shares Up 4.5%
americanbankingnews.com - April 30 at 11:39 AM
What Analysts Think About TG Therapeutics, Inc. (NASDAQ:TGTX)’s Potential RaiseWhat Analysts Think About TG Therapeutics, Inc. (NASDAQ:TGTX)’s Potential Raise
stocksregister.com - April 28 at 1:08 PM
TG Therapeutics, Inc. (NASDAQ:TGTX) Could See Prices Soar In The Coming MonthsTG Therapeutics, Inc. (NASDAQ:TGTX) Could See Prices Soar In The Coming Months
marketingsentinel.com - April 27 at 3:07 PM
TG Therapeutics (NASDAQ:TGTX)  Shares Down 4.6% TG Therapeutics (NASDAQ:TGTX) Shares Down 4.6%
americanbankingnews.com - April 27 at 2:32 PM
TG Therapeutics And Samsung Biologics Expand Ublituximab ManufacturingTG Therapeutics And Samsung Biologics Expand Ublituximab Manufacturing
finance.yahoo.com - April 26 at 1:25 PM
The Goldman Sachs Group Initiates Coverage on TG Therapeutics (NASDAQ:TGTX)The Goldman Sachs Group Initiates Coverage on TG Therapeutics (NASDAQ:TGTX)
americanbankingnews.com - April 26 at 11:32 AM
TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $89.00TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $89.00
marketbeat.com - April 26 at 9:21 AM
TG Therapeutics (NASDAQ:TGTX) Price Target Increased to $89.00 by Analysts at HC WainwrightTG Therapeutics (NASDAQ:TGTX) Price Target Increased to $89.00 by Analysts at HC Wainwright
americanbankingnews.com - April 26 at 9:00 AM
TG Therapeutics to Participate in the B. Riley Securities Neuroscience ConferenceTG Therapeutics to Participate in the B. Riley Securities Neuroscience Conference
finance.yahoo.com - April 26 at 8:24 AM
Samsung Biologics, TG Therapeutics Expand Collaboration For Manufacture Of UblituximabSamsung Biologics, TG Therapeutics Expand Collaboration For Manufacture Of Ublituximab
nasdaq.com - April 26 at 12:08 AM
TG Therapeutics launches late-stage study of triple combination of UkoniqTG Therapeutics launches late-stage study of triple combination of Ukoniq
seekingalpha.com - April 22 at 2:05 PM
Will TG Therapeutics, Inc. (NASDAQ:TGTX) in 2021 Be Worth Your Money?Will TG Therapeutics, Inc. (NASDAQ:TGTX) in 2021 Be Worth Your Money?
marketingsentinel.com - April 21 at 2:17 PM
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and VenetoclaxTG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and Venetoclax
finance.yahoo.com - April 21 at 9:17 AM
Here’s Why TG Therapeutics, Inc. (NASDAQ:TGTX) is an Attractive Pick for Investors NowHere’s Why TG Therapeutics, Inc. (NASDAQ:TGTX) is an Attractive Pick for Investors Now
stocksregister.com - April 20 at 12:57 PM
TG Therapeutics (NASDAQ:TGTX) Receives New Coverage from Analysts at The Goldman Sachs GroupTG Therapeutics (NASDAQ:TGTX) Receives New Coverage from Analysts at The Goldman Sachs Group
americanbankingnews.com - April 20 at 8:02 AM
Positive data in hand, TG Therapeutics readies MS drug for FDA reviewPositive data in hand, TG Therapeutics readies MS drug for FDA review
biopharmadive.com - April 19 at 4:50 PM
TG Therapeutics (NASDAQ:TGTX) PT Raised to $89.00 at HC WainwrightTG Therapeutics (NASDAQ:TGTX) PT Raised to $89.00 at HC Wainwright
americanbankingnews.com - April 19 at 8:02 AM
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trialTG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
pharmatimes.com - April 19 at 6:50 AM
PPG, Alcoa rise; Bank of New York, Marathon Oil fallPPG, Alcoa rise; Bank of New York, Marathon Oil fall
marketbeat.com - April 16 at 4:33 PM
DateCompanyBrokerageAction
2/22/2021GW PharmaceuticalsRaymond JamesReiterated Rating
2/4/2021GW PharmaceuticalsCitigroupDowngrade
2/4/2021GW PharmaceuticalsSVB LeerinkDowngrade
2/4/2021GW PharmaceuticalsMorgan StanleyReiterated Rating
2/4/2021GW PharmaceuticalsHC WainwrightDowngrade
2/3/2021GW PharmaceuticalsCantor FitzgeraldDowngrade
2/3/2021GW PharmaceuticalsNorthland SecuritiesDowngrade
2/3/2021GW PharmaceuticalsNeedham & Company LLCReiterated Rating
8/10/2020GW PharmaceuticalsGuggenheimLower Price Target
8/7/2020GW PharmaceuticalsThe Goldman Sachs GroupSet Price Target
8/7/2020GW PharmaceuticalsBank of AmericaReiterated Rating
8/3/2020GW PharmaceuticalsOppenheimerReiterated Rating
7/14/2020GW PharmaceuticalsStifel NicolausDowngrade
6/30/2020GW PharmaceuticalsEvercore ISIBoost Price Target
3/18/2021Ascendis Pharma A/SCanaccord GenuityBoost Price Target
3/17/2021Ascendis Pharma A/SCredit Suisse GroupLower Price Target
12/17/2020Ascendis Pharma A/SBerenberg BankInitiated Coverage
11/12/2020Ascendis Pharma A/SWells Fargo & CompanyBoost Price Target
9/30/2020Ascendis Pharma A/SWedbushBoost Price Target
9/14/2020Ascendis Pharma A/SJPMorgan Chase & Co.Initiated Coverage
5/20/2020Ascendis Pharma A/SCSFBBoost Price Target
5/6/2021Ultragenyx PharmaceuticalCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgrade
2/12/2021Ultragenyx PharmaceuticalPiper SandlerBoost Price Target
2/12/2021Ultragenyx PharmaceuticalBarclaysBoost Price Target
1/11/2021Ultragenyx PharmaceuticalRobert W. BairdBoost Price Target
10/28/2020Ultragenyx PharmaceuticalTruistBoost Price Target
2/8/2021Arrowhead PharmaceuticalsB. RileyBoost Price Target
2/5/2021Arrowhead PharmaceuticalsChardan CapitalBoost Price Target
12/15/2020Arrowhead PharmaceuticalsUBS GroupInitiated Coverage
11/24/2020Arrowhead PharmaceuticalsRoyal Bank of CanadaBoost Price Target
11/19/2020Arrowhead PharmaceuticalsSmith Barney CitigroupInitiated Coverage
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.